ACP
CRBP icon

Acuta Capital Partners’s Corbus Pharmaceuticals CRBP Stock Holding History

Acuta Capital Partners’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-9,667
Closed -$2.39M – 66
2017
Q1 		$2.39M Buy
+9,667
New +$2.37M 0.57% 38

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acuta Capital Partners's CRBP Position: Q4 2024 in Review

Acuta Capital Partners sold out of Corbus Pharmaceuticals (CRBP) in Q4 2024, closing a stake of 18,500 shares — an estimated $382K sold.

Acuta Capital Partners first reported a position in CRBP in Q3 2016 and held it in 3 quarters. The position peaked at $2.92M in Q2 2024. 99 funds tracked by Wall St. Rank hold CRBP as of Q4 2024.

  • Acuta Capital Partners reported no remaining Corbus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 18,500 Corbus Pharmaceuticals shares in Q4 2024, an estimated $382K.
  • Acuta Capital Partners first reported a position in Corbus Pharmaceuticals in Q3 2016 and held it in 3 quarters.
  • Acuta Capital Partners's Corbus Pharmaceuticals position peaked at $2.92M in Q2 2024.
  • 99 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2024.

Based on Acuta Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.